Piper Sandler analyst Dave Westenberg upgraded Myriad Genetics (NASDAQ: MYGN) from Neutral to Overweight with a price target of $12.50 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE